CODIAK BIOSCIENCES INC (CDAK) Stock News
NASDAQ:CDAK - Nasdaq - US1920101060 - Common Stock - Currency: USD
CDAK Latest News, Press Relases and Analysis
Why Bullfrog AI Holdings Shares Are Trading Higher By 73%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Secoo Holding Limited (NASDAQ: SECO) shares surged 138% to $1.43.
Why AMC Entertainment Holdings Shares Are Trading Lower By 25%; Here Are 20 Stocks Moving Premarket
Gainers AMC Entertainment Hldg Pref Equity Units (NYSE: APE) gained 28.4% to $1.90 in pre-market trading. AMC Entertainment Holdings stated it agreed to settle litigation and move forward with converting its preferred stock into common shares.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to dive into the biggest pre-market stock movers for Tuesday morning with all the latest news traders need to know about!
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time for another dive into the biggest pre-market stock movers for Thursday with all the companies traders need to watch!
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Tuesday!
Why Is Codiak BioSciences (CDAK) Stock Down 52% Today?
Codiak BioSciences (CDAK) stock is falling hard on Monday after the company announced plans for an asset sale via a Chapter 11 bankruptcy.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Welcome back and get ready for another day of trading with a breakdown of the biggest pre-market stock movers for Monday!
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning! It's time for another dive into the biggest pre-market stock movers with the shares rising and falling on Tuesday!
Codiak BioSciences to Participate 5th Annual Evercore ISI HealthCONx Conference
CAMBRIDGE, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the...
Codiak BioSciences Reports Third Quarter 2022 Financial Results and Operational Progress
– Patient enrollment continuing in Phase 1 clinical trial of exoASO™-STAT6 in patients with advanced hepatocellular carcinoma; preliminary data anticipated...
Codiak Presents Preclinical Data Demonstrating its Pan Beta-Coronavirus Vaccine Elicits Broad Protective Immunity Against Known Variants of SARS-CoV-2 and Related Sarbecoviruses
– Data support advancement of Codiak’s engineered exosome bivalent vaccine candidate toward IND-enabling studies – CAMBRIDGE, Mass., Oct. 12, 2022 ...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Investors can start off the day with a breakdown of the biggest pre-market stock movers for Tuesday and the news moving those shares!
Codiak Announces Pricing of $20 Million Public Offering of Common Stock and Warrants
CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK) (“Codiak”), a clinical-stage biopharmaceutical company...
Codiak Announces Proposed Public Offering of Common Stock and Warrants
CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK) (“Codiak”), a clinical-stage biopharmaceutical company...
Codiak BioSciences Announces Program Reprioritization and Corporate Restructuring
– Enrollment continues in Phase 1 clinical trial of IV-administered exoASO™-STAT6 in patients with advanced hepatocellular carcinoma – –...